Cerulea Clinical Trials

Science and Research

ISEE2009 (Gather 2)

An Open-Label Extension (OLE) Phase 3 Trial To Assess The Safety Of Intravitreal Administration Of Avacincaptad Pegol (Complement C5 Inhibitor) In Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (Gather 2)

Overview

An open-label extension study for those patients who have completed participation in the Gather2 trial for Geographic atrophy. Participants will receive monthly intravitreal administrations of Avacincaptad Pegol (Complement C5 Inhibitor) for 18 months.

  • Principal Investigator
Dr Thanh Nguyen

Related Pages